Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 28 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACIE CORONMEUSE from Herstal, company number BE0738601154, closed financial year 2025 with a result of € 364 after tax. For that financial year PHARMACIE CORONMEUSE recorded a gross margin of € 149,236 and equity of € -122,310. Compared with financial year 2024, the result moved from € -40,291 to € 364. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 25, 2026.
€ -122,310
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 364
▲ still € 40,291 loss in 2024
Profit after tax over the fiscal year.
€ 18,496
▲ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -142,310.
People and assets in 2025
€ 148,686
▲ 34% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 46,957
▲ 121% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 31,490
▲ 26% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 96,605 | € 86,327 | € 70,808 | € 149,236 | ▲ 111% |
| Profit after taxes | € -32,803 | € -43,783 | € -40,291 | € 364 | ▲ € 40,655 |
| Equity | € -38,600 | € -82,383 | € -122,674 | € -122,310 | |
| Total debts | € 129,601 | € 205,773 | € 252,757 | € 282,238 | ▲ 12% |
| Cash | € 4,017 | € 4,395 | € 12,956 | € 18,496 | ▲ 43% |
| Retained profit | € -58,600 | € -102,383 | € -142,674 | € -142,310 | |
| Balance sheet total | € 91,001 | € 123,390 | € 130,083 | € 159,928 | ▲ 23% |
Key figures of PHARMACIE CORONMEUSE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE CORONMEUSE?
What happened at PHARMACIE CORONMEUSE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 364. filed late Source: NBB ↗
- New establishment in Herstal. KBO
- Start of the company according to the CBE. KBO
In short
From € 32,803 loss in 2022 to € 364 profit in 2025.
Best year ever: 2025, with € 364 profit.
A new publication or filing at PHARMACIE CORONMEUSE? We notify you, reason included.
Follow PHARMACIE CORONMEUSEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMACIE CORONMEUSE are Karine IPPOLITO and Bernard IPPOLITO. The same people are also behind K.B.I. CONSTRUCT, SEIGNEURIE MICHELANGE and PHARMACIE SOLVAY. Karine IPPOLITO is also behind KBI GESTION.
Directors
According to the 2025 annual accounts
Karine IPPOLITO
Director
Also active at: K.B.I. CONSTRUCT, SEIGNEURIE MICHELANGE, PHARMACIE SOLVAY, KBI GESTION
Establishments
Establishment units
Physical locations of this company
En Hayeneux 201
4040 Herstal
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.601.154
- VAT number
- BE 0738.601.154
- Registered office
- En Hayeneux 201, 4040 Herstal
- Names & denominations
- PHARMACIE CORONMEUSE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 November 2019
- Peppol
- Active · Active since 20 Nov 2020
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten